All posts by imreal

Memorial Healthcare System Launches First Pancreas Transplant Program in Broward County


Dr. Basit Javaid and Dr. Seyed Ghasemian of Memorial Transplant Institute

“With the addition of the pancreas transplant program, we further enhance our reputation as a leading transplant center in the region, with the advanced expertise to take on the most complex cases,” said Dr. Javaid.

Memorial Healthcare System has launched a new pancreas transplant program, complementing Memorial Transplant Institute’s existing pediatric and adult kidney and heart transplant services. This new program is a significant step forward in the field of organ transplantation in Broward County, as it is the only one offering patients with diabetes and other related conditions a chance at a new life with a healthy pancreas.

Abdominal transplant program at Memorial is led by two renowned experts in the field: Dr. Basit Javaid, a transplant nephrologist with more than 25 years of experience facilitating transplantation with excellent post-transplant outcomes for patients, serves as chief of Abdominal Transplant Medicine; and Dr. Seyed Ghasemian, who has more than 30 years of experience with organ transplantations, serves as chief of Abdominal Transplant Surgery Program.

“With the addition of the pancreas transplant program, we further enhance our reputation as a leading transplant center in the region, with the advanced expertise to take on the most complex cases,” said Dr. Javaid. “Together, our transplant nephrologists, surgeons, nurse coordinators, dieticians, social workers, and other healthcare specialists are committed to ensuring positive outcomes for our patients.”

The Need

Patients experiencing kidney failure due to having insulin-dependent diabetes could qualify for a simultaneous pancreas and kidney transplant (SPK), affording a cure to both diabetes and kidney failure.

According to CDC estimates, of almost 130,000 persons in the US who initiated treatment for end-stage renal disease (ESRD) in 2020, nearly 60,000 had diabetes as the underlying cause of kidney failure. Some of these patients would be best suited for SPK transplants.

“Pancreas transplants occur most often in conjunction with kidney transplants for patients who have advanced kidney disease caused by diabetes,” said Dr. Javaid. “A simultaneous pancreas and kidney transplant will treat a patient’s kidney disease, freeing them from dialysis, as well as the requirement for blood sugar monitoring and insulin – a remarkable improvement in their quality of life.”

Memorial ’s pancreas transplant program received approval from UNOS (United Network for Organ Sharing) in April 2023.

“The launch of the pancreas transplant program is an important milestone for Memorial Transplant Institute and its team of experts who continue to reach new heights for the benefit of their patients and families,” said Peter Powers, CEO of Memorial Regional Hospital, which houses the Institute.

The pancreas is a large organ behind the stomach that produces insulin to regulate blood sugar and helps with digestion. When it produces little or no insulin, as is the case with people with diabetes, the body can’t sustain its blood sugar in a normal range. Serious medical complications can occur, including kidney disease, heart attack, stroke, and premature death.

For more information, please call 954-265-7450 or visit http://www.mhs.net/transplant.

About Memorial Transplant Institute

Memorial Transplant Institute, based at Memorial Regional Hospital and including Joe DiMaggio Children’s Hospital, is the only program in Broward County to offer adult and pediatric heart and kidney transplants, and adult pancreas transplants. Memorial Healthcare System has received various federal approvals from UNOS (United Network for Organ Sharing), authorizing: Joe DiMaggio Children’s Hospital’s pediatric heart transplant program in 2010; Memorial Cardiac and Vascular Institute’s adult heart transplant program in 2014; the adult and pediatric kidney transplant program in 2017; and the pancreas transplant program in 2023. For more information about transplantation or donation, call 954-265-7450 or visit http://www.mhs.net/transplant.

Share article on social media or email:

ABSTRAX Principal Scientist Dr. Iain Oswald Wins the ElSohly Award for Discovery of “The Gas” Compounds in Cannabis


www.abstraxtech.com

“Our principal research scientist’s drive for exploring the chemical properties of cannabis and propensity for thinking outside the box is a catalyst for driving ABSTRAX to innovate game-changing discoveries, products and services,” says Max Koby, CEO of ABSTRAX.

ABSTRAX is excited to announce that Iain Oswald, PhD, its Principal Research Scientist, has been awarded the prestigious ElSohly Award in Cannabis Chemistry research for the discovery of a new class of volatile sulfur compounds responsible for the characteristic gassy, skunky aroma produced by cannabis. Oswald received the award on March 21 at the National American Chemical Society in Indianapolis via the Cannabis Chemistry Subdivision (CANN).

“We are exceedingly proud of our principal research scientist, Iain, for his shared passion, dedication and hard work,” said Max Koby, Co-Founder and CEO of ABSTRAX. “Iain’s drive for exploring the chemical properties of cannabis and propensity for thinking outside the box is a catalyst for driving ABSTRAX to innovate game-changing discoveries, products and services.”

At the award ceremony, Oswald was invited to give a presentation detailing his research, which saw ABSTRAX uncover an entirely new family of compounds responsible for the cannabis’ gassy, skunky scent. Using 2-Dimensional gas chromatography (2DGC) coupled with mass spectrometry, flame ionization detection, and sulfur chemiluminescence, the team discovered key volatile sulfur compounds (VSCs) – organic compounds containing sulfur – that directly correlate to the pungent aroma of cannabis rather than terpenes as previously believed. The ubiquity and importance of these compounds in cannabis have since led the authors to coin this class of compounds as Cannasulfur Compounds (CSCs).

“I’m thrilled that ABSTRAX’s discoveries have been noticed and appreciated,” said Dr. Oswald. “It’s important to note that this is just the beginning – there are numerous other cannabis compounds waiting to be identified and potential therapeutic benefits to be discovered.”

CANN was founded in 2015 to build a home within the American Chemical Society for cannabis chemists. The organization established the ElSohly Award in honor of Dr. Mahmoud ElSohly, a legendary cannabis chemist scientist who has made countless contributions to the field. The award provides researchers, students, and industry professionals with resources to present their work at the ElSohly Award Symposium annually at the Spring American Chemical Society National Meeting. Along with Oswald, the three other 2023 award recipients include Nick Jikomes, PhD, Director of Science & Innovation for Leafly; Brodie Thomson, Chemistry Ph.D. candidate at the University of British Columbia; and Dr. Nirit Bernstein, Research Scientist at the Agricultural Research Organization.

For more information, visit https://abstraxtech.com/pages/terpene-research .

About ABSTRAX

Leveraging its proven background in cannabis research, ABSTRAX is the leader in the research, development, and production of botanically-derived and cannabis-inspired terpenes that create unforgettable sensorial experiences. Headquartered in California, the company owns and operates a state-of-the-art type 7 licensed research and manufacturing lab where it’s award-winning product developers and scientists leverage the most advanced strain analysis technology to extract and study aroma compounds via three-dimensional analysis, allowing for each and every compound within a plant to be named and studied. The company has partnered with many of the best cultivators in the industry to study their cannabis profiles and create the world’s most advanced terpene formulations. As a result of its efforts, ABSTRAX offers the largest terpene catalog of the most popular strains – botanically-derived terpene blends and isolates native to cannabis. These ingredients, also known as functional flavors and aromas, are used in vapes, concentrates, edibles, beer, essential oils, fragrances, cosmetics, topicals, tinctures, alcohol, food and beverage, personal care, and more. The company works with internationally recognized brands and provides unparalleled cannabis research, innovation, and custom formulations to create products that engage and thrill consumers. ABSTRAX also devotes significant resources to developing the highest terpene standards and best practices in the industry. The company has developed a robust quality management system including Gas Chromatography analysis and molecular distillation of natural ingredients to achieve the highest purity standards. Investigating and ensuring that ingredients used in its own products, and products within its industry, are safe for consumption. The terpene industry is a rapidly growing segment of the global flavor and fragrance market, which is expected to grow to $35 billion by 2024. This market segment includes the cannabis, CBD, skincare, cosmetics, health and wellness, food and beverage industries. For more information, visit AbstraxTech.com.

Share article on social media or email:

Intech Unveils a Game-Changing Private-Labelled Modular Retractor System


Intech, the market leader in the manufacturing of orthopedic medical devices, today releases a fully validated system for US and EU markets that enables a variety of access to the spine for Medical Device companies and hospitals. This launch complements the introduction of the MIS lateral retractor system to address gaps in access to the spine.

“This game-changing MRS significantly enhances the safety and convenience of surgical retraction for both patients and medical staff, while its modularity and ergonomics allows surgeons for flexibility when accessing the spine” said Romain Ibled, Global Sales Director. “It is especially suitable for OEMs and Group Purchasing Organizations that aim to provide hospitals with cost-effective and state-of-the-art devices.”

Solving the Most Complex Engineering Challenges in the Industry

Developed by intechLabs, in close cooperation with prominent medical device companies and skilled surgeons, the Intech Modular Retractor System was meticulously designed to provide flexibility in the Operation Room. The versatile kit enables various configurations, including pedicle based, midline or four-blade frame-based, to facilitate safe and efficient access to the Spine for implant placement.

Access our free guide today or contact our Intech Sales team to schedule an evaluation.

About Intech

Intech is a global market leader and game-changer in the manufacturing of complex orthopedic medical devices. It all starts with innovation, and nobody knows this better than Intech. With manufacturing facilities around the world and unique initiatives and savoir-faire, Intech is at the forefront of technological innovation in the field of orthopedic devices manufacturing as well as asset management, ensuring optimal patient care is delivered day in day out. This is who we are. We tech care.

Share article on social media or email:

Haag-Streit Launches Surgical Chair 900 for Ophthalmic Surgeons


News Image

Haag-Streit is proud to announce the launch of the Surgical Chair 900. The Surgical Chair 900 (previously known as CO:RE Surgical Chair) is the first chair to consider every aspect of the ophthalmic surgeon’s experience in the surgical suite.

Ophthalmic surgeons are at risk of musculoskeletal injuries and chronic pain, especially when working in a surgical chair that does not provide optimal support or mobility. Haag-Streit collaborated with ophthalmologists to understand their unique challenges and created an ergonomic solution. The Surgical Chair 900 promotes better posture and comfort with both vertical and horizontal lumbar support. It also accommodates surgeons of varying heights with seat adjustability for perfect hip and leg alignment.

The chair’s design allows for a full range of motion. The armless seat back provides support without impeding the arms and elbows, while ergonomically placed pedal controls allow the user to effortlessly raise or lower the seat and lock it into place. The base and column were also designed for easy cleaning and disinfection.

Jeff Sieve, CEO & President, Haag-Streit USA, said, “At Haag-Streit, we strongly believe in the importance of ergonomics and its impact on overall wellness. We are committed to providing high-quality equipment that meets the ergonomic needs of eye care professionals. Investing in ergonomic equipment is not only beneficial for the physician’s well-being and career longevity, but can also lead to improved productivity, accuracy, and patient care. The Surgical Chair 900 supports ideal ergonomic positioning, promoting a healthier and more comfortable work environment.”

The Surgical Chair 900 will be showcased at the Haag-Streit booth (Booth 927) at ASCRS 2023 in San Diego. Attendees are invited to visit the booth for product demonstrations from Saturday, May 6 to Monday, May 8, 2023. In addition, there will be ergonomic discussions with Michael E. Snyder, MD on May 6 from 3:15 PM to 4:15 PM PT and with Yuri McKee, MD on May 7 from 11:30 AM – 12:30 PM PT in the Haag-Streit booth.

For more information on the Surgical Chair 900 or to schedule an evaluation, please visit hssurgicalchair.com.

Share article on social media or email:

Marc Fischer to Speak at the 2023 AAN Annual Meeting about NeurCare, a Remote Patient Monitoring Solution to Track Neurological Conditions


News Image

“NeurCare aims to revolutionize patient care with smartphone technology for remote monitoring and early detection of cognitive conditions”

Marc Fischer, CEO and Co-Founder of Dogtown Media, is scheduled to speak at the 75th American Academy of Neurology (AAN) Annual Meeting about his innovative venture, NeurCare, and the remote monitoring of neurological patients. The presentation will take place on Thursday, April 27th, at 11:45 AM EST, both in-person in Boston and live online. The session is titled “Remote Monitoring of Neurological Patients.”

“I’m deeply grateful to the AAN for this opportunity to present NeurCare to the world’s leading neurology experts. Their insights and feedback are crucial to fulfilling our mission,” said Marc Fischer.

The AAN Annual Meeting, which will be held from April 22-27, 2023, offers a diverse program covering a wide range of topics and specialties in neurology. It provides valuable educational and networking opportunities for attendees, including advanced practice providers, business administrators, general neurologists, medical students, neurohospitalists, non-neurologists, residents, and specialist neurologists.

Fischer’s presentation will focus on the NeurCare app, a mobile health solution developed by Dogtown Media in collaboration with the National Institutes of Health (NIH). NeurCare is designed to remotely monitor patients with neurological disorders such as Multiple Sclerosis, Parkinson’s, Alzheimer’s, and provide early detection of neurotoxicity due to CAR T-Cell immunotherapy treatments.

The worldwide shortage of neurologists and recent COVID-related restrictions have led to fewer neurological exams, resulting in delayed diagnosis and suboptimal patient care. NeurCare aims to address this gap in care by using smartphone-embedded sensors to measure various neurological functions autonomously, right from a patient’s homes.

Fischer’s session will discuss the development and testing of NeurCare’s smartphone tests, which evaluate fine finger movements with differing contributions of specific neurological domains. The study conducted on multiple sclerosis patients has demonstrated promising results, suggesting that smartphone apps like NeurCare can one day recreate the entire neurological examination.

“Presenting NeurCare at the AAN Annual Meeting is an honor, and we’re excited to collaborate with the world’s leading neurologists to drive innovation and enhance patient outcomes in the field of neurology,” said Marc Fischer, CEO and Co-Founder of Dogtown Media.

As a recognized leader in mobile app development and healthcare innovation, Dogtown Media is dedicated to improving patient outcomes and addressing critical healthcare challenges. The company has been honored with several accolades, including being named an awardee in the Improving Detection of Neurotoxicity in Immunotherapies QuickFire Challenge by Johnson & Johnson Innovation LLC. As an mHealth app developer Dogtown Media has created over 250 mobile apps in industries including Healthcare App Development, IoT, and Artificial Intelligence.

For more information about Marc Fischer’s presentation at the 2023 AAN Annual Meeting or the NeurCare app, please visit http://www.neurcare.com

Share article on social media or email:

Implementing Clinical Trial Analytics to Predict Trial Outcomes, Upcoming Webinar Hosted by Xtalks


As clinical operations teams become leaner and more cost-constrained, there is a growing demand for more advanced clinical trial analytics tools to better manage fragmented data.

Over the past decade, clinical trial data has become increasingly complex, leading to disconnects between key stakeholders and inefficiencies within drug development. As clinical operations teams become leaner and more cost-constrained, there is a growing demand for more advanced clinical trial analytics tools to better manage fragmented data.

In this webinar, the featured speakers will walk through four case studies and review all aspects of applying analytics to a study from operational and technical implementation to return on investment (ROI) and key performance indicators (KPIs) to measure success.

Register for this webinar to explore the evolution of clinical trial analytics and how they help predict clinical trial outcomes.

Join Rohit Nambisan, CEO & Co-Founder, Lokavant; and Bill Symonds, CEO, Enzyvant, for the live webinar on Tuesday, May 16, 2023, at 1pm EDT (10am PDT).

For more information, or to register for this event, visit Implementing Clinical Trial Analytics to Predict Trial Outcomes.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

Preclinical Models for the Identification of Chemotherapy Predictive Signatures in Pancreatic Cancer, Upcoming Webinar Hosted by Xtalks


This webinar will address the importance of thorough target validation in the initial stages of pharmaceutical development, as incomplete preclinical validation can lead to efficacy and toxicity setbacks.

Currently, chemotherapy is the primary mode of treatment for pancreatic ductal adenocarcinoma (PDAC), a highly aggressive form of pancreatic cancer. However, selection of regimens is mainly based on patient performance and expected efficacy. The establishment of molecular predictors of chemotherapeutic efficacy is crucial to improve patient prognosis through personalized treatment based on molecular analysis.

The Pancreatic Cancer Team at the Cancer Research Center of Marseille has developed RNA-based signatures to predict the efficacy of all drugs used to treat PDAC. They utilized preclinical models such as PDAC primary cell cultures (PCC), patient-derived xenografts (PDX) and patient-derived organoids (PDO) to overcome limitations of individual models. By combining all three, they produced unbiased RNA-based signatures that are predictive of chemotherapeutic treatments in PDAC. This strategy has yielded improved predictive signatures validated in different patient cohorts, which have demonstrated significant associations with overall, disease-free and progression-free survival.

This webinar will address the importance of thorough target validation in the initial stages of pharmaceutical development, as incomplete preclinical validation can lead to efficacy and toxicity setbacks. The webinar will also highlight strategies for investigating target validation with a focus on PDAC 2D and 3D cell models, including the use of CRISPR target modulation and real-time proliferation. These innovative approaches hold great promise for advancing the field of drug discovery and personalized medicine in pancreatic cancer.

Join the featured speakers for an informative webinar on unlocking the synergy in preclinical models and the importance of target validation for the personalized treatment of pancreatic cancer.

Join Dr. Nelson Dusetti, Research Director at the Cancer Research Center of Marseille, INSERM U.1068; and Dr. Nicolas Ancellin, Senior Program Director/Site Director, Strategic Projects, Oncodesign Services, for the live webinar on Tuesday, May 16, 2023, at 11am EDT (4pm BST/UK).

For more information, or to register for this event, visit Preclinical Models for the Identification of Chemotherapy Predictive Signatures in Pancreatic Cancer.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

Ideal Option Releases 2022 ID Patient Outcomes Report to Show Effectiveness of Medication-Assisted Treatment for Fentanyl, Heroin, Methamphetamine and Cocaine


Ideal Option, a national leader in outpatient medication-assisted treatment for addiction to opioids and other substances, has released its 2022 Annual Patient Outcomes Report for patients living in Idaho. This report contains an aggregated view of patients’ geographic and demographic characteristics, their stage and duration of care, adherence to medication and their substance use over time based on lab specimens collected during 2022 from more than 900 patients. The data support the effectiveness of treating addiction with FDA-approved medications combined with regular lab testing to verify medication adherence, create accountability and ensure patient safety.

Among Idaho patients who remained in treatment from initiation to the maintenance stage of care during 2022, the report shows:

  • 90% less total opioid use
  • 98% less fentanyl use
  • 90% less heroin use
  • 86% less methamphetamine use
  • 81% less cocaine use

The report also reveals synthetic drug use continuing to rise among enrolling patients in 2022, particularly fentanyl. Fentanyl is regularly mixed with other illicit drugs to make them more addictive, often without the user knowing. “Polysubstance use disorder is now the most common diagnosis at Ideal Option,” said Tim Kilgallon, CEO at Ideal Option. “In 2022, 62% of all Idaho patients tested positive for two or more substances at enrollment, and 26% tested positive for three or more substances.”

The data corroborate state reports of the increasingly prevalent role that fentanyl plays in the substance use epidemic. According to the Idaho Department of Health and Welfare, 44% of overdose deaths in Idaho in 2021 involved synthetic opioids, such as fentanyl, as compared to 21% in 2020, and 12% in 2019. In addition, according to a report from the Oregon-Idaho High Intensity Drug Trafficking Area task force, “Fentanyl and methamphetamine were the most significant threats to Oregon and Idaho during 2021 based on drug seizures, drug related death data, initiative interviews, and surveys conducted in early 2022.”

Ideal Option data show that standard treatment for opioid use disorder dramatically reduces the use of methamphetamine in patients who test positive for both. View the full Ideal Option 2022 Annual Patient Outcomes Report for Idaho here: https://www.idealoption.com/patient-outcomes.

Ideal Option has helped more than 65,000 patients through a network of nearly 90 outpatient clinics across 11 states: Alaska, Arkansas, Idaho, Maryland, Minnesota, Montana, Nebraska, New Mexico, North Dakota, Oregon and Washington. With no waitlists and most forms of insurance accepted, including Medicare and Medicaid, patients can typically get started on treatment for fentanyl, heroin, methamphetamine, alcohol, or other substances within 1-3 business days. Patients can make an appointment by calling 1.877.522.1275 or visiting http://www.idealoption.com.

About Ideal Option 

Headquartered in Kennewick, Washington, Ideal Option was founded in 2012 and has since helped more than 65,000 patients through a network of nearly 90 office-based medication-assisted treatment (MAT) clinics across 11 states. With a mission to serve under-served communities, Ideal Option accepts most forms of insurance including Medicaid and Medicare. Financial assistance and payment plans are also available.  Ideal Option’s team of medical providers carry certifications in Addiction and Emergency Medicine, Internal, and Family Medicine, among other specialties. The company also employs social workers, caseworkers, counselors, and mental health practitioners. This holistic approach helps drive positive outcomes, including family stability, stable housing, improved overall health, and reduced rates of recidivism.  In all the communities it serves, Ideal Option collaborates with existing stakeholders and providers to improve the continuum of care. This approach includes partnerships with emergency rooms and county jail systems, where individuals with substance use disorder often appear, as well as collaborating with numerous support agencies and municipal programs addressing social needs such as housing, mental health, and nutrition support.

Share article on social media or email:

Ideal Option Releases 2022 NM Patient Outcomes Report to Show Effectiveness of Medication-Assisted Treatment for Fentanyl, Heroin, Methamphetamine and Cocaine


Ideal Option, a national leader in outpatient medication-assisted treatment for addiction to opioids and other substances, has released its 2022 Annual Patient Outcomes Report for patients living in New Mexico. This report contains an aggregated view of patients’ geographic and demographic characteristics, their stage and duration of care, adherence to medication and their substance use over time based on lab specimens collected during 2022 from more than 500 patients. The data support the effectiveness of treating addiction with FDA-approved medications combined with regular lab testing to verify medication adherence, create accountability and ensure patient safety. Among New Mexico patients who remained in treatment from initiation to the maintenance stage of care during 2022, the report shows:

  • 89% less total opioid use
  • 94% less fentanyl use
  • 94% less heroin use
  • 88% less methamphetamine use
  • 87% less cocaine use

The report also reveals synthetic drug use continuing to rise among enrolling patients in 2022, particularly fentanyl. Fentanyl is regularly mixed with other illicit drugs to make them more addictive, often without the user knowing. “Polysubstance use disorder is now the most common diagnosis at Ideal Option,” said Tim Kilgallon, CEO at Ideal Option. “In 2022, 60% of all New Mexico patients tested positive for two or more substances at enrollment, and 22% tested positive for three or more substances.” The data corroborate state reports of the increasingly prevalent role that fentanyl plays in the substance use epidemic. According to the CDC National Center for Health Statistics, there were 617 overdose deaths due to synthetic opioids reported in New Mexico during the 12-month period ending in January 2022, an 85% increase from the 333 deaths reported during the same period the year before. In addition, according to the New Mexico Department of Health, methamphetamine and fentanyl are the most likely substances involved in drug overdose deaths across the state. Ideal Option data show that standard treatment for opioid use disorder dramatically reduces the use of methamphetamine in patients who test positive for both. View the full Ideal Option 2022 Annual Patient Outcomes Report for New Mexico here: https://www.idealoption.com/patient-outcomes. Ideal Option has helped more than 65,000 patients through a network of nearly 90 outpatient clinics across 11 states: Alaska, Arkansas, Idaho, Maryland, Minnesota, Montana, Nebraska, New Mexico, North Dakota, Oregon and Washington. With no waitlists and most forms of insurance accepted, including Medicare and Medicaid, patients can typically get started on treatment for fentanyl, heroin, methamphetamine, alcohol, or other substances within 1-3 business days. Patients can make an appointment by calling 1.877.522.1275 or visiting http://www.idealoption.com.

About Ideal Option 

Headquartered in Kennewick, Washington, Ideal Option was founded in 2012 and has since helped more than 65,000 patients through a network of nearly 90 office-based medication-assisted treatment (MAT) clinics across 11 states. With a mission to serve under-served communities, Ideal Option accepts most forms of insurance including Medicaid and Medicare. Financial assistance and payment plans are also available.  Ideal Option’s team of medical providers carry certifications in Addiction and Emergency Medicine, Internal, and Family Medicine, among other specialties. The company also employs social workers, caseworkers, counselors, and mental health practitioners. This holistic approach helps drive positive outcomes, including family stability, stable housing, improved overall health, and reduced rates of recidivism.  In all the communities it serves, Ideal Option collaborates with existing stakeholders and providers to improve the continuum of care. This approach includes partnerships with emergency rooms and county jail systems, where individuals with substance use disorder often appear, as well as collaborating with numerous support agencies and municipal programs addressing social needs such as housing, mental health, and nutrition support.

Share article on social media or email: